Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy (Q30240687)

12 June 2017

1 reference

title

Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy (English)

1 reference

12 June 2017

1 reference

0 references

cryptococcal meningitis

1 reference

Thomas S Harrison

7

0 references

Angela Loyse

object named as

Angela Loyse

6

0 references

Matthew C. Fisher

object named as

Matthew C Fisher

4

0 references

Joseph N. Jarvis

2

object named as

Joseph N Jarvis

1 reference

12 June 2017

Peter R Williamson

1

1 reference

12 June 2017

Anil A Panackal

3

1 reference

12 June 2017

Síle F Molloy

5

1 reference

12 June 2017

language of work or name

English

0 references

publication date

25 November 2016

1 reference

12 June 2017

Nature Reviews Neurology

1 reference

12 June 2017

13

1 reference

12 June 2017

13-24

1 reference

12 June 2017

1

1 reference

Cost-effective diagnostic checklists for meningitis in resource-limited settings

12 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Epidemiology of meningitis in an HIV-infected Ugandan cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Epidemiology of cryptococcal meningitis in the US: 1997-2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcus: from environmental saprophyte to global pathogen.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcus neoformans host adaptation: toward biological evidence of dormancy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Emerging fungal threats to animal, plant and ecosystem health

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000-2012.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Clinical and host differences between infections with the two varieties of Cryptococcus neoformans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

A mutation in the human Uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Adult-onset immunodeficiency in Thailand and Taiwan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

STAT3 mutations in the hyper-IgE syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Hyper-IgM immunodeficiency with disseminated cryptococcosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Association of Fcγ receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The tools for virulence of Cryptococcus neoformans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Early clinical and subclinical visual evoked potential and Humphrey's visual field defects in cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Early mycological treatment failure in AIDS-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Prognostic factors in cryptococcal meningitis. A study in 111 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Rapid tests for sexually transmitted infections (STIs): the way forward

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal meningitis. False-negative antigen test results and cultures in nonimmunosuppressed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Pitfalls in Serological Diagnosis of Cryptococcus gattii Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Combination antifungal therapy for cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

How I treat cryptococcosis in organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Dramatic improvement of severe cryptococcosis-induced immune reconstitution syndrome with adalimumab in a renal transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Dexamethasone in Cryptococcus gattii central nervous system infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The damage-response framework of microbial pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Phased implementation of screening for cryptococcal disease in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Sapronosis: a distinctive type of infectious agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Evolution of intracellular pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi--the Cryptococcus neoformans paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

The capsule of the fungal pathogen Cryptococcus neoformans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Genome Evolution and Innovation across the Four Major Lineages of Cryptococcus gattii

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.167

Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome

31 March 2020

1 reference

12 December 2020

Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.

1 reference

12 December 2020

Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia

1 reference

12 December 2020

Fundamentals of fungal molecular population genetic analyses.

1 reference

12 December 2020

Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures

1 reference

12 December 2020

10.1038/NRNEUROL.2016.167

Identifiers

DOI

1 reference

Dimensions Publication ID

12 June 2017

0 references

1 reference